Cannabis is no stranger to medicine or commerce. Its origins date as far back as 8000 BC when hemp (a part of the Cannabis plant) was first documented as a domesticated plant. Since then, its fibers have been used for rope and within textiles and its seeds as a source of nutrition and food. The ancients were also quick to recognize its medicinal properties. It has been used throughout the centuries for treating pain and inflammation as well as diarrhea and other digestive issues.
In modern times, cannabis, or its alternate alias, marijuana, has been more closely associated with recreational drug use, but its medicinal properties are also increasingly recognized and its medical use on the rise. Even before Canada became the first industrialized country to legalize adult-use of cannabis back in 2018, cannabis was enjoying a strong run. Many US states began to legalize medical marijuana use already in the 1990s and were joined by many other US states and EU countries in the decades that followed. Cannabis is now legal in 33 US states and most EU countries allow or are considering the medical use of chemical compounds called cannabinoids derived from cannabis plants.
When medically prescribed, cannabis is most commonly used to control pain as well as a myriad of other therapies including epilepsy, multiple sclerosis, Parkinson’s disease, depression, diabetes and a host of other neurological and digestive tract disorders. Adverse side effects include dependence, neurological impairment, and other chronic diseases, but research suggests that health risks are much less than those associated with other legal substances like alcohol and opiates.
Given its medical efficacy, pharmaceutical companies are taking advantage of a more relaxed legal environment to conduct research into cannabis-related treatments that can be easily swallowed, rubbed or inhaled rather than smoked. Moreover, given a growing perception that cannabis consumption is safer than alcohol, the beverage industry is also taking note and partnering with cannabis producers to develop drinks especially for more health-conscious market segments.
Legal marijuana sales exceeded USD 21 billion globally in 2020 according to BDSA, a US-based cannabis data analytics provider1. And the US cannabis beverage market is expected to expand ten-fold to USD 374 million by 2022. Cannabis companies have also entered the financial mainstream. Wall Street welcomed its first marijuana IPO by a Canadian cannabis producer already in 2018. Moreover, according to Viridian, a financial advisory firm, in the first quarter of 2021 cannabis companies raised nearly USD 4.3 billion in debt and equity2.
Given the growing medical evidence, legislative approval, and social acceptance of cannabis as a treatment tool, Robeco is predominantly positive towards the development of cannabis-related medical products. However, given existing uncertainties surrounding adverse health effects of cannabis use in unmonitored settings, it cautions investments in companies that generate revenues of 5% or more from recreational cannabis production as well as companies that generate revenues of 10% or more from recreational cannabis retail products.
Moreover, Robeco’s Active Ownership Team will engage with individual companies to address and monitor potential sustainability risks and their impact on performance.
1 “Cannabis reignites corporate interests as it edges towards mainstream.” Financial Times, April 4, 2021. https://www.ft.com/content/f52b8bd9-867a-46ad-9808-d5d3afce739e
2 “Wall Street welcomes first marijuana IPO.” Financial Times, July 19, 2018. https://www.ft.com/content/0e19b2a6-8b28-11e8-bf9e-8771d5404543
The contents of this document have not been reviewed by the Securities and Futures Commission ("SFC") in Hong Kong. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. This document has been distributed by Robeco Hong Kong Limited (‘Robeco’). Robeco is regulated by the SFC in Hong Kong.
This document has been prepared on a confidential basis solely for the recipient and is for information purposes only. Any reproduction or distribution of this documentation, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited. By accepting this documentation, the recipient agrees to the foregoing
This document is intended to provide the reader with information on Robeco’s specific capabilities, but does not constitute a recommendation to buy or sell certain securities or investment products. Investment decisions should only be based on the relevant prospectus and on thorough financial, fiscal and legal advice. Please refer to the relevant offering documents for details including the risk factors before making any investment decisions.
The contents of this document are based upon sources of information believed to be reliable. This document is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
Investment Involves risks. Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future. The value of your investments may fluctuate. Past performance is no indication of current or future performance.
Please read this information carefully.
This website is prepared and issued by Robeco Hong Kong Limited ("Robeco"), which is a corporation licensed by the Securities and Futures Commission in Hong Kong to engage in Type 1 (dealing in securities); Type 4 (advising in securities) and Type 9 (asset management) regulated activities. The Company does not hold client assets and is subject to the licensing condition that it shall seek the SFC’s prior approval before extending services at retail level. This website has not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong.
2. Important risk disclosures
2. Important risk disclosures Robeco Capital Growth Funds (“the Funds”) are distinguished by their respective specific investment policies or any other specific features. Please read carefully for the risks of the Funds:
3. Local legal and sales restrictions
The information contained in the Website is being provided for information purposes.
Neither information nor any opinion expressed on the Website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. The information contained in the Website does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, most recent annual and semi-annual reports, which can be all be obtained free of charge at www.robeco.com/hk/en and at the Robeco Hong Kong office.
4. Use of the Website
The information is based on certain assumptions, information and conditions applicable at a certain time and may be subject to change at any time without notice. Robeco aims to provide accurate, complete and up-to-date information, obtained from sources of information believed to be reliable. Persons accessing the Website are responsible for their choice and use of the information.
5. Investment performance
No assurance can be given that the investment objective of any investment products will be achieved. No representation or promise as to the performance of any investment products or the return on an investment is made. The value of your investments may fluctuate. The value of the assets of Robeco investment products may also fluctuate as a result of the investment policy and/or the developments on the financial markets. Results obtained in the past are no guarantee for the future. Past performance, projection, or forecast included in this Website should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Fund performance figures are based on the month-end trading prices and are calculated on a total return basis with dividends reinvested. Return figures versus the benchmark show the investment management result before management and/or performance fees; the fund returns are with dividends reinvested and based on net asset values with prices and exchange rates of the valuation moment of the benchmark.
Investments involve risks. Past performance is not a guide to future performance. Potential investors should read the terms and conditions contained in the relevant offering documents and in particular the investment policies and the risk factors before any investment decision is made. Investors should ensure they fully understand the risks associated with the fund and should also consider their own investment objective and risk tolerance level. Investors are reminded that the value and income (if any) from shares of the fund may be volatile and could change substantially within a short period of time, and investors may not get back the amount they have invested in the fund. If in doubt, please seek independent financial and professional advice.
6. Third party websites
This website includes material from third parties or links to websites maintained by third parties some of which is supplied by companies that are not affiliated to Robeco. Following links to any other off-site pages or websites of third parties shall be at the own risk of the person following such link. Robeco has not reviewed any of the websites linked to or referred to by the Website and does not endorse or accept any responsibility for their content nor the products, services or other items offered through them. Robeco shall have no liability for any losses or damages arising from the use of or reliance on the information contained on websites of third parties, including, without limitation, any loss of profit or any other direct or indirect damage. Third party off-site pages or websites are provided for informational purposes only.
7. Limitation of liability
Robeco as well as (possible) other suppliers of information to the Website accept no responsibility for the contents of the Website or the information or recommendations contained herein, which moreover may be changed without notice.
Robeco assumes no responsibility for ensuring, and makes no warranty, that the functioning of the Website will be uninterrupted or error-free. Robeco assumes no responsibility for the consequences of e-mail messages regarding a Robeco (transaction) service, which either cannot be received or sent, are damaged, received or sent incorrectly, or not received or sent on time.
Neither will Robeco be liable for any loss or damage that may result from access to and use of the Website.
8. Intellectual property
All copyrights, patents, intellectual and other property, and licenses regarding the information on the Website are held and obtained by Robeco. These rights will not be passed to persons accessing this information.
10. Applicable law
The Website shall be governed by and construed in accordance with the laws of Hong Kong. All disputes arising out of or in connection with the Website shall be submitted to the exclusive jurisdiction of the courts of Hong Kong.